Keywords: boeh, ingelheim, sales, slump, europe, japan, bloom
Boeh Ingelheim Sales Slump in Europe & Japan, Bloom In USA
Article | 04 August 1998
Boehringer Ingelheim, the privately-owned German drugmaker, says thatalthough sales rose 7.5% to almost 4.3 billion Deutschemarks ($2.41 billion) for the first six months ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
